Abstract

An efficacious vaccine for sheep-associated malignant catarrhal fever (SA-MCF) is important for the livestock industry. Research towards SA-MCF vaccine development is hindered by the absence of culture systems to propagate the causative agent, ovine herpesvirus-2 (OvHV-2), which means its genome cannot be experimentally modified to generate an attenuated vaccine strain. Alternative approaches for vaccine development are needed to deliver OvHV-2 antigens. Bovine herpesvirus 4 (BoHV-4) has been evaluated as a vaccine vector for several viral antigens with promising results. In this study, we genetically engineered BoHV-4 to express OvHV-2 glycoprotein B (gB) and evaluated its efficacy as an SA-MCF vaccine using a rabbit model. The construction of a viable recombinant virus (BoHV-4-AΔTK-OvHV-2-gB) and confirmation of OvHV-2 gB expression were performed in vitro. The immunization of rabbits with BoHV-4-AΔTK-OvHV-2-gB elicited strong humoral responses to OvHV-2 gB, including neutralizing antibodies. Following intra-nasal challenge with a lethal dose of OvHV-2, 42.9% of the OvHV-2 gB vaccinated rabbits were protected against SA-MCF, while all rabbits in the mock-vaccinated group succumbed to SA-MCF. Overall, OvHV-2 gB delivered by the recombinant BoHV-4 was immunogenic and partly protective against SA-MCF in rabbits. These are promising results towards an SA-MCF vaccine; however, improvements are needed to increase protection rates.

Highlights

  • PCR resulted in the amplification of expected band sizes using the junction PCR

  • The sequencing of amplicons matched with the expected sequences of the inserted cassettes and their location into the Bovine herpesvirus 4 (BoHV-4) TK locus

  • bacterial artificial chromosome (BAC) recombineering using E. coli SW102 successfully replaced the KGK gene cassette in the pBAC-BoHV-4-A∆TK-KGK with the CMV-OvgB-V5 cassette resulting in construction of pBAC-BoHV-4-A∆TK-ovine herpesvirus-2 (OvHV-2)-glycoprotein B (gB) (Figure 1)

Read more

Summary

Introduction

Ovine herpesvirus 2 (OvHV-2) causes a frequently fatal disease called sheep-associated malignant catarrhal fever (SA-MCF) in several ungulates, such as bison, cattle, pigs, and deer [1,2]. In the absence of effective treatments for the disease, vaccine development comes as an option for the livestock industry. SA-MCF can have significant economic impact, in the growing bison industry in the US and Canada, due to the high susceptibility of bison to the disease [3]. Cattle are more resistant to SA-MCF than bison, the disease remains an intermittent problem for the cattle industry as losses can on occasion be high [4]. One of the major constraints for the development of an SA-MCF vaccine is the inability to propagate OvHV-2 in cell culture. Since the virus cannot be modified or attenuated in vitro, alternative approaches for delivering OvHV-2 antigens for immunization are of utmost importance

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call